Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.90 |
| ▸ | PDE6C | P51160 | 2/20 | 0.90 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611957 | 1.00 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL147337 | 0.95 | PDE5A (1.00) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL18069561 | 0.92 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7959160 | 0.92 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL5964550 | 0.88 | PDE5A (0.70) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.88 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29357402 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20100267736-A1 | METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF PHOSPHODIESTERASE INHIBITORS | THOMAS THOMAS N | 2010-10-21 | — | — | US | claimed |
| US-20100267735-A1 | METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF PHOSPHODIESTERASE INHIBITORS | THOMAS THOMAS N | 2010-10-21 | — | — | US | claimed |
| US-7737147-B2 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | THOMAS THOMAS NADACKAL | 2010-06-15 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | SWITCH BIOTECH, LLC | 2008-02-28 | — | — | US | claimed |
| EP-1858554-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-11-28 | — | — | EP | claimed |
| EP-1759700-A1 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2007-03-07 | — | — | EP | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | claimed |
| WO-2001070211-A2 | L-ARGININE AND PHOSPHODIESTERASE (PDE) INHIBITOR SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | claimed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885HDAC1 4868/4885 |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE5A 2/4885PDE6C 22/4885HDAC1 2453/4885 |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 16/4885HDAC1 1617/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885HDAC1 4868/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885HDAC1 4868/4885 |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 8/4885HDAC1 171/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885HDAC1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.